Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From trace element to therapeutic application: The emerging role of selenium nanoparticles in cancer therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Formulation and Characterization of Patent Blue Dye Nanoliposome Labeled with <sup>99m</sup>Tc-HMPAO and <i>In Vivo</i> Evaluation by Sentinel Lymph Node Mapping.

Lymphatic research and biology·2026
Same author

Cytokine storm in severe bacterial infections: A Mini-Review of molecular insights and treatment strategies.

Molecular biology reports·2026
Same author

The Safety and Efficacy of an Immunomodulator Garlic-Based Cream (LeishG1) for Treating Uncomplicated Cutaneous Leishmaniasis: A Single-Blind, Multi-Center Study.

Health science reports·2025
Same author

Erysipeloid Cutaneous Leishmaniasis in the Old World: A Systematic Review.

International journal of dermatology·2025
Same author

Comparative <i>in vitro</i> susceptibility of clinical <i>Leishmania</i> isolates to miltefosine and oleylphosphocholine.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: Feb 17, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.4K

Liposomal adjuvant development for leishmaniasis vaccines.

Anis Askarizadeh1, Mahmoud Reza Jaafari2, Ali Khamesipour3

  • 1Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Therapeutic Advances in Vaccines
|December 5, 2017
PubMed
Summary

Liposomal adjuvants offer a promising strategy to improve leishmaniasis vaccines by enhancing antigen delivery to immune cells. Optimizing liposome properties is key for successful vaccine development against this parasitic disease.

Keywords:
adjuvantleishmaniasisliposomevaccine

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Related Experiment Videos

Last Updated: Feb 17, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection

Published on: September 1, 2023

2.4K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.2K

Area of Science:

  • Immunology
  • Vaccinology
  • Parasitology

Background:

  • Leishmaniasis is a severe parasitic disease with no current human vaccine.
  • Lack of effective adjuvants or delivery systems limits current vaccine efficacy.
  • Recovery from cutaneous leishmaniasis confers long-lasting immunity, suggesting vaccine potential.

Purpose of the Study:

  • To review the role of liposomal adjuvants in developing vaccines against Leishmania.
  • To discuss physicochemical properties of liposomes relevant to vaccine formulation.
  • To suggest strategies for successful liposomal vaccine design.

Main Methods:

  • Review of existing literature on liposomal adjuvants and Leishmania vaccines.
  • Analysis of liposome physicochemical properties (composition, charge, size).
  • Discussion of formulation strategies for antigen and immunostimulator delivery.

Main Results:

  • Liposomes effectively deliver antigens and immunostimulators to antigen-presenting cells (APCs).
  • Liposome properties modulate immune response magnitude and T-helper bias.
  • Versatile liposome structure allows incorporation of various vaccine components.

Conclusions:

  • Liposomal adjuvants are a valuable strategy for enhancing Leishmania vaccine efficacy.
  • Careful consideration of physicochemical properties is crucial for liposomal vaccine formulation.
  • Optimized liposomal vaccine strategies hold promise for future leishmaniasis prevention.